medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back Next >>

Ann Hepatol 2018; 17 (3)

Therapeutic Effect of HGF on NASH Mice Through HGF/c-Met and JAK2-STAT3 Signalling Pathway

Li N, Dou Z, Liu J, Chai B, Li Y, An X, Chu P, Zhang X

Language: English
References: 28
Page: 501-510
PDF size: 679.65 Kb.


ABSTRACT

Introduction and aim. Hepatocyte growth factor (HGF) has been shown to ameliorate liver inflammation and fibrosis; however, the mechanism underlying its effects in non-alcoholic steatohepatitis (NASH) is unclear. This study aimed to analyse the relationship between the JAK2-STAT3 signalling pathway and the ameliorating effect of HGF on NASH. Material and methods. Mice were fed a high-fat diet (HFD) for 16 weeks, and then plasma and hepatic tissues were collected. Histological and clinical chemistry assays were performed to assess liver disease. The mRNA and protein levels of JAK2, STAT3, and c-Met were assessed by realtime PCR and western blotting, respectively. Results. Serum ALT, AST, and TG levels were increased in NASH mice. Histological analysis showed different degrees of steatosis, inflammatory infiltrates, and fibrosis in HFD animals. Exogenous administration of recombinant human (rh) HGF via the tail vein for 14 days markedly decreased ALT and AST to levels lower than those in the control group. Compared with the levels in HFD mice, c-Met, p-c-Met, JAK2, p-JAK2, and p-STAT3 levels were increased in mice that were administered HGF (P ‹ 0.05). Furthermore, silencing of HGF or blocking of its receptor c-Met affected JAK2 and STAT3 protein phosphorylation. Conclusions. Excess HGF highly probable improved NASH liver function. Combined with its ligand, c-Met, HGF may promote the phosphorylation of JAK2-STAT3 and inhibit inflammation in NASH. Therefore, it may be potentially useful treatment for NASH.


REFERENCES

  1. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-65.

  2. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 2011; 26: 188-202.

  3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.

  4. Narmada BC, Kang Y, Venkatraman L, Peng Q, Sakban RB, Nugraha B, Jiang X, et al. Hepatic stellate cell-targeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum Gene Ther 2013; 24: 508-19.

  5. Tojima H, Kakizaki S, Kosone T, Horiguchi N, Yamazaki Y, Sato K, Takagi H, et al. Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol Int 2012; 6: 620-30.

  6. Agrawal RP, Sheroan V, Ola V, Sulemani AA, Singh N, Sirohi P, Gothwal S, et al. Hepatocyte growth factor, adiponectin and hepatic histopathology in non-alcoholic steatohepatitis. J Assoc Physicians India 2013; 61: 789-92.

  7. Kroy DC, Schumacher F, Ramadori P, Hatting M, Bergheim I, Gassler N, Boekschoten MV, et al. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. J Hepatol 2014; 61: 883-90.

  8. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 15; 117: 1281-3.

  9. Yu HC, Qin HY, He F, Wang L, Fu W, Liu D, Guo FC, et al. Canonical notch pathway protects hepatocytes from ischemia/reperfusion injury in mice by repressing reactive oxygen species production through JAK2/STAT3 signaling. Hepatology 2011; 54: 979-88.

  10. Kim MD, Kim SS, Cha HY, Jang SH, Chang DY, Kim W, Suh- Kim H, et al. Therapeutic effect of hepatocyte growth factorsecreting mesenchymal stem cells in a rat model of liver fibrosis. Exp Mol Med 2014; 46: e110.

  11. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-20.

  12. Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007; 67: 3529-34.

  13. Saito Y, Kon S, Fujiwara Y, Nakayama Y, Kurotaki D, Fukuda N, Kimura C, et al. Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum Gene Ther 2007; 18: 1205-14.

  14. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011; 71: 6601-10.

  15. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeuticinhibition. Cytokine Growth Factor Rev 2002; 13: 41-59.

  16. Tahara M, Matsumoto K, Nukiwa T, Nakamura T. Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. J Clin Invest 1999; 103: 313-20.

  17. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.

  18. Ernst M, Putoczki TL Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 2012; 39: 711-8.

  19. Zheng P, Ji G, Ma Z, Liu T, Xin L, Wu H, Liang X, et al. Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 2009; 37: 69-83.

  20. Akhurst B, Matthews V, Husk K, Smyth MJ, Abraham LJ, Yeoh GC. Differential lymphotoxin-beta and interferon gamma signaling during mouse liver regeneration induced by chronic and acute injury. Hepatology 2005; 41: 327-35.

  21. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 588-610.

  22. Liu WT, Jing YY, Yu GF, Chen H, Han ZP, Yu DD, Fan QM, et al. Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53. Cell Cycle 2016; 15: 886-94.

  23. Cao HH, Cheng CY, Su T, Fu XQ, Guo H, Li T, Tse AK, et al. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion. Mol Cancer 2015; 14: 103.

  24. Miller AM, Wang H, Bertola A, Park O, Horiguchi N, Ki SH, Yin S, et al. Inflammation-associated interleukin-6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and non-alcoholic fatty liver diseases in interleukin- 10-deficient mice. Hepatology 2011; 54: 846-56.

  25. Paredes-Turrubiarte G, González-Chávez A, Pérez-Tamayo R, Salazar-Vázquez BY, Hernández VS, Garibay-Nieto N, Fragoso JM, et al. Severity of non-fatty liver disease is associated with high systemic levels of tumornecrosis factor alpha and low serum interleukin 10 in morbidly obese patients. Clin Exp Med 2016; 16: 193-202.

  26. Kamimoto M, Mizuno S, Nakamura T. Reciprocal regulation of IL-6 and IL-10 balance by HGF via recruitment of heme oxygenase- 1 in macrophages for attenuation of liver injury in a mouse model of endotoxemia. Int J Mol Med 2009; 24: 161-70.

  27. Yamaura K, Ito K, Tsukioka K, Wada Y, Makiuchi A, Sakaguchi M, Akashima T, et al. Suppression of acute and chronic rejection by hepatocyte growth factor in amurine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 2004; 110: 1650-7.

  28. Kamimoto M, Mizuno S, Nakamura T. Reciprocal regulation of IL- 6 and IL-10 balance by HGF via recruitment of heme oxygenase- 1 in macrophages for attenuation of liver injury in a mouse model of endotoxemia. Int J Mol Med 2009; 24: 161-70.




2020     |     www.medigraphic.com